In addition, as a strong activator that may trigger a long-term susceptibility to allergic airway inflammation, α-GalCer has also been shown to be an attenuator of Th2-type responses and AHR in antigen-specific asthma models, depending on the timing, administration route and the in vivo model used [20–23]. Here, AHR is linked to asthma.